| Previous Close | 118.740 |
| Open | 118.570 |
| Bid | 120.200 x 200 |
| Ask | 120.640 x 100 |
| Day's Range | 118.540 - 123.620 |
| 52 Week Range | 96.520 - 192.940 |
| Volume | 640,921 |
| Avg. Volume | 1,111,318 |
| Market Cap | 6.57B |
| Beta | 2.31 |
| PE Ratio (TTM) | -12.19 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks•7 hours ago
Biotech Stock Roundup: FDA Nod for First Cancer Biosimilar, HALO up on Deals, Raised Outlook
Data presentations, regulatory updates and licensing deals were among the key highlights this week with the focus being on the FDA approval of the first cancer biosimilar - Amgen's (AMGN) Mvasi.
- Zacks•2 days ago
TESARO Ovarian Cancer Drug Zejula Gets Positive CHMP Opinion
TESARO's (TSRO) marketing application for approval of its PARP-inhbitor Zejula as monotherapy for the maintenance treatment of ovarian cancer gets positive CHMP opinion.
- Capital Cube•9 days ago
ETFs with exposure to TESARO, Inc. : September 12, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to TESARO, Inc. Here are 5 ETFs with the largest exposure to TSRO-US. Comparing the performance and risk of TESARO, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
